You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,765,683


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,765,683
Title:T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy
Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
Inventor(s): Peled; Amnon (Tel-Aviv, IL), Begin; Michal (Jerusalem, IL), Beider; Katia (Jerusalem, IL), Abraham; Michal (Mevasseret Zion, IL)
Assignee: Biokine Therapeutics Ltd. (Nes Ziona, IL)
Application Number:13/360,751
Patent Claims:1. A method for treating lymphoma in a subject, comprising administering to the subject a therapeutically effective amount of an anti-CD20 antibody and a peptide having an amino acid sequence as set forth in SEQ ID NO:1, thereby treating the lymphoma.

2. The method of claim 1, wherein said anti-CD20 antibody comprises rituximab.

3. A method for inducing lymphoma cell death in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-CD20 antibody and a peptide having an amino acid sequence as set forth in SEQ ID NO:1, thereby inducing lymphoma cell death.

4. The method of claim 3, wherein said anti-CD20 antibody comprises rituximab.

5. A method for increasing the sensitivity of lymphoma cells to an anti-CD20 antibody, comprising administering to a subject in need thereof a sensitizing-effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO:1 in concurrent or sequential combination with the anti-CD20 antibody, thereby increasing the sensitivity of lymphoma cells to the anti-CD20 antibody.

6. The method of claim 5, wherein said anti-CD20 antibody comprises rituximab.

Details for Patent 8,765,683

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2026-12-21
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2026-12-21
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2026-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.